Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 11 April 2017, 11:42 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Easy to Drink Bergamot Flavor

TOKYO, Apr 11, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. Chocola BB Gold Rich is a luxurious combination of 16 active ingredients, the highest number in the Chocola BB series. It contains active ingredients including B-complex vitamins and taurine 1500mg to help a fatigued body produce energy, and six natural herbs carefully selected by female developers to please female consumers, including angelica acutiloba, ginseng, and royal jelly. The bergamot orange flavor, which is also used in Earl Grey tea and other products, is easy to drink, and the gold and pink packaging is elegantly designed to give off a sense of luxury. This boxed supplement drink from the Chocola BB brand has been designed to be approachable for female consumers.

Chocola BB Gold Rich

In recent years, along with the increasing social advancement of women, the market catering to female supplement drink consumers is also growing. Additionally, consumers drink different products depending on their level of fatigue. This product is designed to respond to the needs of women who want a high performance drink. Chocola BB Gold Rich is a speedy fatigue reliever perfect for busy women in the office or at home.

The Chocola BB supplement drink series includes Chocola BB Light 2 for day-to-day fatigue, Chocola BB Royal 2 for extreme fatigue, and Chocola BB Hyper for weak constitutions, all of which are marketed as designated quasi-drug products designed to help relieve fatigue.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
July 8, 2025 08:31 HKT/SGT
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
June 2, 2025 16:46 HKT/SGT
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
May 28, 2025 16:45 HKT/SGT
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 21, 2025 14:00 HKT/SGT
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 16, 2025 16:21 HKT/SGT
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
Apr 30, 2025 13:17 HKT/SGT
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 18, 2025 15:52 HKT/SGT
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: